title: Target-mediated disposition model describing the dynamics of IL12 and IFNγ after administration of a mifepristone-inducible adenoviral vector for IL-12 expression in mice.
abstract: Interleukin-12 (IL12) is a cytokine with potential applications in the treatment of cancer given the potent immune response that it triggers, in part due to its ability to stimulate expression of interferon-γ (IFNγ). To avoid the toxicity associated with systemic exposure to IL12, a high-capacity adenoviral vector carrying a liver-specific, mifepristone-inducible IL12 expression system (HC-Ad/RUmIL12) has been developed. However, the maintenance of IL12 expression at therapeutic levels is compromised by the inhibitory effect of IFNγ on inducible systems. The aim of this work is to develop a semi-mechanistic model to characterize the relationship between IL12 and IFNγ in wild-type and knock-out mice for the IFNγ receptor treated with HC-Ad/RUmIL12 under different dosing regimens in order to better understand the key mechanisms controlling the system. Rapid binding was considered to account for target-mediated disposition exhibited by both cytokines (equilibrium dissociation constant were 18 and 2.28 pM for IL12 and IFNγ, respectively). The final model included: (1) IFNγ receptor turnover, (2) irreversible free cytokine elimination from the serum compartment, (3) internalization of the IL12 receptor complex, (4) IL12 expression upregulated by the co-administration of the adenoviral vector and mifepristone and downregulated by the IFNγ receptor, and (5) synthesis of IFNγ controlled by the relative increments in the bound IL12. In conclusion, a model simultaneously describing the kinetics of IL12 and IFNγ in the context of gene therapy was developed and validated with additional data. The model was applied to design an experimental dosing protocol intended to maintain sustained therapeutic IL12 levels.
authors.affiliation: Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, C/ Irunlarrea 1, 31008, Pamplona, Navarra, Spain.
authors.forename: Zinnia Patricia
authors.initials: ZP
authors.lastname: Parra-Guillen
authors.forename: Alvaro
authors.initials: A
authors.lastname: Janda
authors.forename: Pilar
authors.initials: P
authors.lastname: Alzuguren
authors.forename: Pedro
authors.initials: P
authors.lastname: Berraondo
authors.forename: Ruben
authors.initials: R
authors.lastname: Hernandez-Alcoceba
authors.forename: Iñaki F
authors.initials: IF
authors.lastname: Troconiz
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors; D007371:Interferon-gamma / Q000235:genetics*; D018664:Interleukin-12 / Q000235:genetics*; D051379:Mice; D008810:Mice, Inbred C57BL; D015735:Mifepristone / Q000494:pharmacology*; D008954:Models, Biological; D017471:Receptors, Interferon / Q000378:metabolism; D000096743:Interferon gamma Receptor
chemical_list: D007371:Interferon-gamma; D018664:Interleukin-12; D015735:Mifepristone; D017471:Receptors, Interferon; D000096743:Interferon gamma Receptor